Biohaven Ltd.
biohaven.comWhat Do They Do?
Develops potential medicines for people with immune, neurological and cancer diseases.
10-K for FY2025, filed Mar 2, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 10, 2026
−$137.3MView ↗
- ▼ −31% (Loss)
- vs −$198.1M in Q2 FY2025
-
Aug 26, 2026
Agrees to license its Kv7 platform to SK Biopharmaceuticals
SKBP will pay a $400 million upfront fee, up to $150 million in milestones, and sales royalties; the license takes effect only after closing conditions are met.
Sources
8-K, filed Aug 26, 2026
Under the License Agreement, SKBP will pay BBIL a non-creditable and non-refundable upfront fee of $400 million, consisting of $350 million…View ↗
Clinical development focus
The earlier report described programs across neuroscience, immunology and cancer; the latest centers clinical development on epilepsy, immune diseases, and neuromuscular or metabolic conditions.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 2, 2026We are a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing…View ↗
In the fourth quarter of 2025, we initiated strategic portfolio and cost-optimization measures to prioritize three key, late-stage…View ↗
Who Do They Compete With?
Competes with Glenmark
10-K for FY2025, filed Mar 2, 2026Since the Nobel Prize-winning discovery of the capsaicin receptor TRPV1 in 1997, members of the TRP cation channel family have been elusive…View ↗
Loading...
